Amicus Therapeutics, Inc. provided earnings guidance for the full year 2023. For the full-year 2023, the Company expected total revenue growth between 14 and 18% at CER.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.02 USD | +2.14% | +1.01% | -29.39% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.39% | 2.97B | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2023